Investors

[{"d":"2024-02-16","n":"Enzymatica’s Board of Directors decides on a new rights issue of SEK 27.4 million","u":"/media/press-releases/2024/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-sek-27-4-million/"},{"d":"2024-02-16","n":"Year-end report 2023: Scientific and regulatory progress generating international interest","u":"/media/press-releases/2024/year-end-report-2023-scientific-and-regulatory-progress-generating-international-interest/"},{"d":"2024-02-16","n":"Enzymatica’s rights issue is secured to 100 percent","u":"/media/press-releases/2024/enzymaticas-rights-issue-is-secured-to-100-percent/"},{"d":"2024-02-19","n":"Enzymatica publishes information memorandum about rights issue of shares","u":"/media/press-releases/2024/enzymatica-publishes-information-memorandum-about-rights-issue-of-shares/"},{"d":"2024-03-11","n":"ColdZyme® certified under the new EU medical device regulation (MDR)","u":"/media/press-releases/2024/coldzyme-certified-under-the-new-eu-medical-device-regulation-mdr/"},{"d":"2024-03-14","n":"Enzymatica announces outcome of new rights issue","u":"/media/press-releases/2024/enzymatica-announces-outcome-of-new-rights-issue/"},{"d":"2024-03-27","n":"Notice of Annual General Meeting 2024 in Enzymatica AB (publ)","u":"/media/press-releases/2024/notice-of-annual-general-meeting-2024-in-enzymatica-ab-publ/"},{"d":"2024-04-09","n":"Enzymatica publishes annual report for 2023","u":"/media/press-releases/2024/enzymatica-publishes-annual-report-for-2023/"},{"d":"2024-04-25","n":"Interim report Q1/2024: MDR certification opens up great commercial opportunities","u":"/media/press-releases/2024/interim-report-q12024-mdr-certification-opens-up-great-commercial-opportunities/"},{"d":"2024-05-07","n":"Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024","u":"/media/press-releases/2024/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ-on-may-7-2024/"},{"d":"2024-06-13","n":"Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days","u":"/media/press-releases/2024/interim-results-from-independent-clinical-study-of-coldzyme-show-duration-of-illness-lowered-by-approximately-5-days/"},{"d":"2024-07-18","n":"Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million","u":"/media/press-releases/2024/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-approximately-sek-130-million/"},{"d":"2024-07-18","n":"Notice of Extraordinary General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2024/notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2024-07-18","n":"Enzymatica's Board of Directors updates the financial targets","u":"/media/press-releases/2024/enzymaticas-board-of-directors-updates-the-financial-targets/"},{"d":"2024-07-18","n":"Interim report Q2/2024: Enzymatica builds momentum for expansion","u":"/media/press-releases/2024/interim-report-q22024-enzymatica-builds-momentum-for-expansion/"},{"d":"2024-08-06","n":"Bulletin from the extraordinary general meeting of Enzymatica AB (publ) on 6 August 2024","u":"/media/press-releases/2024/bulletin-from-the-extraordinary-general-meeting-of-enzymatica-ab-publ-on-6-august-2024/"},{"d":"2024-08-16","n":"Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.","u":"/media/press-releases/2024/final-results-from-independent-clinical-study-of-coldzyme-show-duration-of-illness-lowered-by-approximately-5-days-/"},{"d":"2024-08-26","n":"Publication of prospectus regarding Enzymatica’s rights issue","u":"/media/press-releases/2024/publication-of-prospectus-regarding-enzymaticas-rights-issue/"},{"d":"2024-09-05","n":"Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load","u":"/media/press-releases/2024/reported-results-on-secondary-endpoints-from-the-university-of-kent-study-on-coldzyme-show-significant-reduction-of-symptoms-lost-training-days-and-viral-load/"},{"d":"2024-09-09","n":"Enzymatica publishes supplementary prospectus","u":"/media/press-releases/2024/enzymatica-publishes-supplementary-prospectus/"},{"d":"2024-09-12","n":"Enzymatica announces outcome of new rights issue","u":"/media/press-releases/2024/enzymatica-announces-outcome-of-new-rights-issue/"},{"d":"2024-11-07","n":"Interim report Q3/2024: Focus on developing existing and new markets","u":"/media/press-releases/2024/interim-report-q32024-focus-on-developing-existing-and-new-markets/"},{"d":"2023-02-17","n":"Interim report Q4/2022: A year that laid the foundation for growth","u":"/media/press-releases/2023/interim-report-q42022-a-year-that-laid-the-foundation-for-growth/"},{"d":"2023-03-31","n":"Notice of Annual General Meeting 2023 in Enzymatica AB (publ)","u":"/media/press-releases/2023/notice-of-annual-general-meeting-2023-in-enzymatica-ab-publ/"},{"d":"2023-04-05","n":"Enzymatica publishes annual report for 2022","u":"/media/press-releases/2023/enzymatica-publishes-annual-report-for-2022/"},{"d":"2023-04-27","n":"Interim report Q1/2023: Strong start to the year – Enzymatica’s growth journey continues according to plan","u":"/media/press-releases/2023/interim-report-q12023-strong-start-to-the-year--enzymaticas-growth-journey-continues-according-to-plan/"},{"d":"2023-05-04","n":"Bulletin from Annual General Meeting of Enzymatica AB (publ)","u":"/media/press-releases/2023/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ/"},{"d":"2023-07-18","n":"Interim report Q2/2023: An exciting and important time ahead","u":"/media/press-releases/2023/interim-report-q22023-an-exciting-and-important-time-ahead/"},{"d":"2023-08-22","n":"New study: ColdZyme breaks viral infection cycle – significantly reducing influenza viral load","u":"/media/press-releases/2023/new-study-coldzyme-breaks-viral-infection-cycle--significantly-reducing-influenza-viral-load/"},{"d":"2023-09-21","n":"Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat","u":"/media/press-releases/2023/interim-report-from-clinical-study-coldzyme-significantly-reduces-rhinovirus-viral-load-and-symptoms-of-sore-throat/"},{"d":"2023-11-07","n":"Interim report Q3/2023: Research results that reshape the competitive landscape","u":"/media/press-releases/2023/interim-report-q32023-research-results-that-reshape-the-competitive-landscape/"},{"d":"2023-11-30","n":"Enzymatica changes Certified Adviser to Carnegie Investment Bank AB (publ)","u":"/media/press-releases/2023/enzymatica-changes-certified-adviser-to-carnegie-investment-bank-ab-publ/"},{"d":"2022-11-16","n":"Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes","u":"/media/press-releases/2022/enzymatica-and-university-of-kent-launch-study-to-explore-prevention-of-upper-respiratory-virus-infections-in-elite-athletes/"},{"d":"2022-11-02","n":"Interim report Q3/2022: A broader role for ColdZyme adds potential for the future","u":"/media/press-releases/2022/interim-report-q32022-a-broader-role-for-coldzyme-adds-potential-for-the-future/"},{"d":"2022-11-01","n":"New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells","u":"/media/press-releases/2022/new-study-confirms-coldzyme-stops-viruses-causing-covid-19-from-adhering-to-human-respiratory-cells/"},{"d":"2022-08-26","n":"Enzymatica announces outcome of new rights issue","u":"/media/press-releases/2022/enzymatica-announces-outcome-of-new-rights-issue/"},{"d":"2022-08-18","n":"Enzymatica publishes supplementary prospectus","u":"/media/press-releases/2022/enzymatica-publishes-supplementary-prospectus/"},{"d":"2022-08-16","n":"ColdZyme also blocks omicron variants BA.4 and BA.5","u":"/media/press-releases/2022/coldzyme-also-blocks-omicron-variants-ba4-and-ba5/"},{"d":"2022-08-05","n":"Publication of prospectus regarding Enzymatica’s rights issue","u":"/media/press-releases/2022/publication-of-prospectus-regarding-enzymaticas-rights-issue/"},{"d":"2022-07-19","n":"Interim report Q2/2022: Improved sales give confidence for the future","u":"/media/press-releases/2022/interim-report-q22022-improved-sales-give-confidence-for-the-future/"},{"d":"2022-07-19","n":"Enzymatica’s Board of Directors decides on a new rights issue of SEK 74.7 million","u":"/media/press-releases/2022/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-sek-747-million/"},{"d":"2022-06-23","n":"ColdZyme blocks omicron virus – according to new research","u":"/media/press-releases/2022/coldzyme-blocks-omicron-virus--according-to-new-research/"},{"d":"2022-06-16","n":"Enzymatica signs loan agreement with major shareholders","u":"/media/press-releases/2022/enzymatica-signs-loan-agreement-with-major-shareholders/"},{"d":"2022-04-28","n":"Bulletin from Annual General Meeting of Enzymatica AB (publ) on 28 April 2022","u":"/media/press-releases/2022/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ-on-28-april-2022/"},{"d":"2022-04-28","n":"Interim report Q1/2022: Our financial targets remain in place","u":"/media/press-releases/2022/interim-report-q12022-our-financial-targets-remain-in-place/"},{"d":"2022-04-11","n":"Article about ColdZyme acquitted from suspicions of research misconduct","u":"/media/press-releases/2022/article-about-coldzyme-acquitted-from-suspicions-of-research-misconduct/"},{"d":"2022-04-04","n":"Enzymatica’s mouth spray to be launched in Turkey","u":"/media/press-releases/2022/enzymaticas-mouth-spray-to-be-launched-in-turkey/"},{"d":"2022-03-31","n":"Enzymatica publishes annual report for 2021","u":"/media/press-releases/2022/enzymatica-publishes-annual-report-for-2021/"},{"d":"2022-03-28","n":"Notice of Annual General Meeting 2022 in Enzymatica AB (publ)","u":"/media/press-releases/2022/notice-of-annual-general-meeting-2022-in-enzymatica-ab-publ/"},{"d":"2022-03-03","n":"Enzymatica’s mouth spray to be launched in Mexico","u":"/media/press-releases/2022/enzymaticas-mouth-spray-to-be-launched-in-mexico/"},{"d":"2022-02-17","n":"Year-end report: Clear signs of favourable market trends after a challenging 2021","u":"/media/press-releases/2022/year-end-report-clear-signs-of-favourable-market-trends-after-a-challenging-2021/"},{"d":"2022-01-12","n":"Enzymatica comments on wrongful wording in Dagens Medicin","u":"/media/press-releases/2022/enzymatica-comments-on-wrongful-wording-in-dagens-medicin/"},{"d":"2021-11-02","n":"The long-term plan remains in challenging times","u":"/media/press-releases/2021/the-long-term-plan-remains-in-challenging-times/"},{"d":"2021-11-02","n":"Enzymatica Board decides on financial targets","u":"/media/press-releases/2021/enzymatica-board-decides-on-financial-targets/"},{"d":"2021-10-18","n":"Bulletin from the extraordinary general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2021/bulletin-from-the-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2021-09-29","n":"Notice of extraordinary general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2021/notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2021-09-08","n":"Claus Egstrand takes office as CEO ahead of schedule","u":"/media/press-releases/2021/claus-egstrand-takes-office-as-ceo-ahead-of-schedule/"},{"d":"2021-08-11","n":"Chinese and US patent authorities issue notices of allowance for patent for key component in cold spray ColdZyme","u":"/media/press-releases/2021/chinese-and-us-patent-authorities-issue-notices-of-allowance-for-patent-for-key-component-in-cold-spray-coldzyme/"},{"d":"2021-07-16","n":"Continued lower sales due to pandemic but some stabilization","u":"/media/press-releases/2021/continued-lower-sales-due-to-pandemic-but-some-stabilization/"},{"d":"2021-07-13","n":"Claus Egstrand appointed new CEO of Enzymatica","u":"/media/press-releases/2021/claus-egstrand-appointed-new-ceo-of-enzymatica/"},{"d":"2021-07-12","n":"Enzymatica and STADA extend agreement on ViruProtect to Vietnam","u":"/media/press-releases/2021/enzymatica-and-stada-extend-agreement-on-viruprotect-to-vietnam/"},{"d":"2021-06-22","n":"Enzymatica appoints new Director of Quality Assurance and Communication Manager","u":"/media/press-releases/2021/enzymatica-appoints-new-director-of-quality-assurance-and-communication-manager/"},{"d":"2021-06-07","n":"Enzymatica announces outcome of new rights issue","u":"/media/press-releases/2021/enzymatica-announces-outcome-of-new-rights-issue/"},{"d":"2021-06-03","n":"Enzymatica launches ColdZyme on Amazon","u":"/media/press-releases/2021/enzymatica-launches-coldzyme-on-amazon/"},{"d":"2021-05-21","n":"Patent for ColdZyme approved in Japan","u":"/media/press-releases/2021/patent-for-coldzyme-approved-in-japan/"},{"d":"2021-05-12","n":"Prospectus for Enzymatica’s rights issue is published","u":"/media/press-releases/2021/prospectus-for-enzymaticas-rights-issue-is-published/"},{"d":"2021-05-05","n":"Bulletin from Annual General Meeting of Enzymatica AB (publ) on 5 May 2021","u":"/media/press-releases/2021/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ-on-5-may-2021/"},{"d":"2021-04-29","n":"Lower sales due to the pandemic but new rights issue secures continued international expansion","u":"/media/press-releases/2021/lower-sales-due-to-the-pandemic-but-new-rights-issue-secures-continued-international-expansion/"},{"d":"2021-03-31","n":"Enzymatica Publication of the Annual Report 2020","u":"/media/press-releases/2021/enzymatica-publication-of-the-annual-report-2020/"},{"d":"2021-03-31","n":"Notice of Annual General Meeting 2021 in Enzymatica AB (publ)","u":"/media/press-releases/2021/notice-of-annual-general-meeting-2021-in-enzymatica-ab-publ/"},{"d":"2021-03-29","n":"Enzymatica’s Board of Directors decides on a new rights issue of SEK 59.1 million","u":"/media/press-releases/2021/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-sek-591-million/"},{"d":"2021-03-22","n":"Enzymatica’s sales and result affected by the pandemic","u":"/media/press-releases/2021/enzymaticas-sales-and-result-affected-by-the-pandemic/"},{"d":"2021-02-18","n":"Positive operating result and almost doubled sales for the fourth quarter","u":"/media/press-releases/2021/positive-operating-result-and-almost-doubled-sales-for-the-fourth-quarter/"},{"d":"2021-02-11","n":"Enzymatica comments on article in Dagens Medicin","u":"/media/press-releases/2021/enzymatica-comments-on-article-in-dagens-medicin/"},{"d":"2021-01-15","n":"New strategic recruitments and organizational changes at Enzymatica","u":"/media/press-releases/2021/new-strategic-recruitments-and-organizational-changes-at-enzymatica/"},{"d":"2020-12-09","n":"STADA agreement extended for the Nordic Region","u":"/media/press-releases/2020/stada-agreement-extended-for-the-nordic-region/"},{"d":"2020-11-12","n":"Enzymatica enters agreement with MS Pharma for MENA","u":"/media/press-releases/2020/enzymatica-enters-agreement-with-ms-pharma-for-mena/"},{"d":"2020-11-03","n":"Continued strong sales increase and positive cash flow in third quarter","u":"/media/press-releases/2020/continued-strong-sales-increase-and-positive-cash-flow-in-third-quarter/"},{"d":"2020-10-21","n":"Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme®","u":"/media/press-releases/2020/enzymatica-enters-agreement-with-sanofi-for-covering-france-and-italy-on-common-cold-spray-coldzyme/"},{"d":"2020-10-13","n":"Enzymatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries","u":"/media/press-releases/2020/enzymatica-and-stada-extend-agreement-on-viruprotect-to-russia-poland-ukraine-and-cis-countries/"},{"d":"2020-10-07","n":"ColdZyme launched in Israel","u":"/media/press-releases/2020/coldzyme-launched-in-israel/"},{"d":"2020-09-28","n":"The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica’s in vitro study on SARS-CoV-2","u":"/media/press-releases/2020/the-journal-of-medical-virology-has-peer-reviewed-approved-and-published-the-results-of-enzymaticas-in-vitro-study-on-sars-cov-2/"},{"d":"2020-09-23","n":"New patents approved for ColdZyme in Japan and Russia","u":"/media/press-releases/2020/new-patents-approved-for-coldzyme-in-japan-and-russia/"},{"d":"2020-09-17","n":"New version – corrected 17 September, 2020 The results of Enzymatica's placebo-controlled, randomized study","u":"/media/press-releases/2020/new-version--corrected-17-september-2020-the-results-of-enzymaticas-placebo-controlled-randomized-study/"},{"d":"2020-08-17","n":"The results of Enzymatica's placebo-controlled, randomized study show statistically significant shorter common colds and good treatment efficacy when using ColdZyme","u":"/media/press-releases/2020/the-results-of-enzymaticas-placebo-controlled-randomized-study-show-statistically-significant-shorter-common-colds-and-good-treatment-efficacy-when-using-coldzyme/"},{"d":"2020-07-20","n":"A new in vitro study shows the ability of ColdZyme to deactivate SARS-CoV-2, the cause of the COVID-19 pandemic","u":"/media/press-releases/2020/a-new-in-vitro-study-shows-the-ability-of-coldzyme-to-deactivate-sars-cov-2-the-cause-of-the-covid-19-pandemic/"},{"d":"2020-07-16","n":"Doubled sales also during the second quarter","u":"/media/press-releases/2020/doubled-sales-also-during-the-second-quarter/"},{"d":"2020-06-03","n":"Shorter duration of common colds for endurance athletes with ColdZyme","u":"/media/press-releases/2020/shorter-duration-of-common-colds-for-endurance-athletes-with-coldzyme/"},{"d":"2020-05-25","n":"Enzymatica and STADA extend agreement for Europe","u":"/media/press-releases/2020/enzymatica-and-stada-extend-agreement-for-europe/"},{"d":"2020-05-19","n":"Grant of European patent for ColdZyme","u":"/media/press-releases/2020/grant-of-european-patent-for-coldzyme/"},{"d":"2020-05-18","n":"Changes in management at Enzymatica","u":"/media/press-releases/2020/changes-in-management-at-enzymatica/"},{"d":"2020-05-05","n":"Bulletin from Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2020/bulletin-from-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2020-05-05","n":"Doubled sales and positive earnings for the first quarter","u":"/media/press-releases/2020/doubled-sales-and-positive-earnings-for-the-first-quarter/"},{"d":"2020-04-24","n":"ColdZyme re-certified to class III in the EU","u":"/media/press-releases/2020/coldzyme-re-certified-to-class-iii-in-the-eu/"},{"d":"2020-04-21","n":"Enzymatica enables postal voting at the Annual General Meeting 2020","u":"/media/press-releases/2020/enzymatica-enables-postal-voting-at-the-annual-general-meeting-2020/"},{"d":"2020-04-03","n":"Notice of annual general meeting 2020 in Enzymatica AB (publ)","u":"/media/press-releases/2020/notice-of-annual-general-meeting-2020-in-enzymatica-ab-publ/"},{"d":"2020-04-02","n":"Enzymatica - publication of the Annual Report 2019","u":"/media/press-releases/2020/enzymatica---publication-of-the-annual-report-2019/"},{"d":"2020-03-27","n":"Enzymatica gets increased sales due to the Corona situation","u":"/media/press-releases/2020/enzymatica-gets-increased-sales-due-to-the-corona-situation/"},{"d":"2020-03-20","n":"Enzymatica signs agreement with Chemipal for Israel","u":"/media/press-releases/2020/enzymatica-signs-agreement-with-chemipal-for-israel/"},{"d":"2020-03-03","n":"Strong results from preventive use of ColdZyme against common cold virus","u":"/media/press-releases/2020/strong-results-from-preventive-use-of-coldzyme-against-common-cold-virus/"},{"d":"2020-02-13","n":"ColdZyme – third largest cold brand in Sweden","u":"/media/press-releases/2020/coldzyme--third-largest-cold-brand-in-sweden/"},{"d":"2020-02-12","n":"Shorter colds and milder symptoms among children who use ColdZyme","u":"/media/press-releases/2020/shorter-colds-and-milder-symptoms-among-children-who-use-coldzyme/"},{"d":"2020-02-03","n":"The European Patent Office recommends grant of a new patent covering a key ingredient in ColdZyme against the common cold","u":"/media/press-releases/2020/the-european-patent-office-recommends-grant-of-a-new-patent-covering-a-key-ingredient-in-coldzyme-against-the-common-cold/"},{"d":"2020-01-28","n":"The Nomination Committee proposes that Fredrik Lindberg is elected to the Board of Directors","u":"/media/press-releases/2020/the-nomination-committee-proposes-that-fredrik-lindberg-is-elected-to-the-board-of-directors/"},{"d":"2020-01-22","n":"Enzymatica signs agreement with Keyuan Trade for China","u":"/media/press-releases/2020/enzymatica-signs-agreement-with-keyuan-trade-for-china/"},{"d":"2020-01-14","n":"ColdZyme launched in Hong Kong","u":"/media/press-releases/2020/coldzyme-launched-in-hong-kong/"},{"d":"2019-12-21","n":"Enzymatica’s CEO resigns","u":"/media/press-releases/2019/enzymaticas-ceo-resigns/"},{"d":"2019-12-13","n":"Enzymatica in agreement for enzyme formulations for the Chinese skin care market","u":"/media/press-releases/2019/enzymatica-in-agreement-for-enzyme-formulations-for-the-chinese-skin-care-market/"},{"d":"2019-11-28","n":"STADA collaboration expands in Germany","u":"/media/press-releases/2019/stada-collaboration-expands-in-germany/"},{"d":"2019-11-05","n":"Very strong increase of sales during the third quarter","u":"/media/press-releases/2019/very-strong-increase-of-sales-during-the-third-quarter/"},{"d":"2019-10-10","n":"Enzymatica recruits new Director of Quality Assurance","u":"/media/press-releases/2019/enzymatica-recruits-new-director-of-quality-assurance/"},{"d":"2019-09-04","n":"Preliminary results of Enzymatica’s placebo-controlled, randomized study did not meet the primary end-point","u":"/media/press-releases/2019/preliminary-results-of-enzymaticas-placebo-controlled-randomized-study-did-not-meet-the-primary-end-point/"},{"d":"2019-08-26","n":"ColdZyme launches with new flavor and new product claims","u":"/media/press-releases/2019/coldzyme-launches-with-new-flavor-and-new-product-claims/"},{"d":"2019-07-17","n":"Good growth in Q2, driven mainly by strong sales in Sweden","u":"/media/press-releases/2019/good-growth-in-q2-driven-mainly-by-strong-sales-in-sweden/"},{"d":"2019-06-19","n":"Enzymatica signs supply agreement with German cosmetic company Maren, amounting to a value of SEK 120 million over a period of three years","u":"/media/press-releases/2019/enzymatica-signs-supply-agreement-with-german-cosmetic-company-maren-amounting-to-a-value-of-sek-120-million-over-a-period-of-three-years/"},{"d":"2019-05-07","n":"Bulletin from Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2019/bulletin-from-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2019-05-07","n":"Continued strong growth in Sweden, but lower total sales during the quarter","u":"/media/press-releases/2019/continued-strong-growth-in-sweden-but-lower-total-sales-during-the-quarter/"},{"d":"2019-05-03","n":"All patients enrolled in Enzymatica’s German placebo-controlled multicentre study with ColdZyme","u":"/media/press-releases/2019/all-patients-enrolled-in-enzymaticas-german-placebo-controlled-multicentre-study-with-coldzyme/"},{"d":"2019-04-16","n":"Enzymatica’s cold spray launched in South Africa","u":"/media/press-releases/2019/enzymaticas-cold-spray-launched-in-south-africa/"},{"d":"2019-02-19","n":"Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany","u":"/media/press-releases/2019/enzymatica-ab-strong-sales-in-the-fourth-quarter-but-lower-sales-for-full-year-2018-driven-by-restrictions-in-germany/"},{"d":"2019-01-30","n":"Enzymatica AB: First patients included in large placebo-controlled multicentre study on ColdZyme","u":"/media/press-releases/2019/enzymatica-ab-first-patients-included-in-large-placebo-controlled-multicentre-study-on-coldzyme/"},{"d":"2019-01-25","n":"Multi-symptom Relief and Improvement of Quality of Life - A Comparative Multicenter Trial on ColdZyme® Mouth Spray in Common Cold","u":"/media/press-releases/2019/multi-symptom-relief-and-improvement-of-quality-of-life---a-comparative-multicenter-trial-on-coldzyme-mouth-spray-in-common-cold/"},{"d":"2019-01-25","n":"Enzymatica AB: Results from German multicentre study strengthen and broaden ColdZyme's product claims","u":"/media/press-releases/2019/enzymatica-ab-results-from-german-multicentre-study-strengthen-and-broaden-coldzymes-product-claims/"},{"d":"2018-12-10","n":"Enzymatica AB: Appeal on Enzymatica's cold spray in Germany overruled","u":"/media/press-releases/2018/enzymatica-ab-appeal-on-enzymaticas-cold-spray-in-germany-overruled/"},{"d":"2018-12-02","n":"Enzymatica AB: Enzymatica raises SEK 98.7 million in completed share issue","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-raises-sek-987-million-in-completed-share-issue/"},{"d":"2018-11-23","n":"Enzymatica signs another agreement in Asia with Evergreen for Hong Kong and Macau","u":"/media/press-releases/2018/enzymatica-signs-another-agreement-in-asia-with-evergreen-for-hong-kong-and-macau/"},{"d":"2018-11-12","n":"Enzymatica AB: Prospectus for Enzymatica's rights issue with preferential rights for existing shareholders published","u":"/media/press-releases/2018/enzymatica-ab-prospectus-for-enzymaticas-rights-issue-with-preferential-rights-for-existing-shareholders-published/"},{"d":"2018-11-05","n":"Enzymatica AB: Bulletin from Extraordinary General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2018/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2018-11-02","n":"Enzymatica AB: Enzymatica's rights issue is secured up to 100 percent","u":"/media/press-releases/2018/enzymatica-ab-enzymaticas-rights-issue-is-secured-up-to-100-percent/"},{"d":"2018-11-01","n":"New British study of endurance athletes shows reduced duration of colds with ColdZyme","u":"/media/press-releases/2018/new-british-study-of-endurance-athletes-shows-reduced-duration-of-colds-with-coldzyme/"},{"d":"2018-10-31","n":"Enzymatica AB: Breakthrough agreement for Japan and lower sales in Q3 due to restrictions in Germany","u":"/media/press-releases/2018/enzymatica-ab-breakthrough-agreement-for-japan-and-lower-sales-in-q3-due-to-restrictions-in-germany/"},{"d":"2018-10-18","n":"Enzymatica AB: Notice of Extraordinary General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2018/enzymatica-ab-notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2018-10-18","n":"Enzymatica AB: The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million","u":"/media/press-releases/2018/enzymatica-ab-the-board-of-directors-of-enzymatica-ab-decides-on-rights-issue-of--sek-987-million/"},{"d":"2018-10-18","n":"Enzymatica AB: Enzymatica signs agreement for the Japanese market","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-for-the-japanese-market/"},{"d":"2018-10-01","n":"Enzymatica AB: Significant benefits from ColdZyme in a major German multicenter study evaluating different common cold symptom scales","u":"/media/press-releases/2018/enzymatica-ab-significant-benefits-from-coldzyme-in-a-major-german-multicenter-study-evaluating-different-common-cold-symptom-scales/"},{"d":"2018-08-29","n":"Enzymatica AB: Appeal of court ruling on Enzymatica's cold spray in Germany","u":"/media/press-releases/2018/enzymatica-ab-appeal-of-court-ruling-on-enzymaticas-cold-spray-in-germany/"},{"d":"2018-07-31","n":"Enzymatica AB: Enzymatica signs agreement for ColdZyme with ABEX Pharmaceutica (Pty) Ltd for South Africa","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-for-coldzyme-with-abex-pharmaceutica-pty-ltd-for-south-africa/"},{"d":"2018-07-17","n":"Enzymatica AB: Lower sales in Q2 but 31% increase for the first half of the year","u":"/media/press-releases/2018/enzymatica-ab-lower-sales-in-q2-but-31-increase-for-the-first-half-of-the-year/"},{"d":"2018-07-16","n":"Enzymatica AB: Court ruling put restrictions on marketing of Enzymatica's cold spray in Germany","u":"/media/press-releases/2018/enzymatica-ab-court-ruling-put-restrictions-on-marketing-of-enzymaticas-cold-spray-in-germany/"},{"d":"2018-06-07","n":"Enzymatica AB: Enzymatica secures funding for operations","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-secures-funding-for-operations/"},{"d":"2018-05-22","n":"Enzymatica AB: Enzymatica signs agreement with Qualia Pharma for Greece and Cyprus","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-with-qualia-pharma-for-greece-and-cyprus/"},{"d":"2018-04-26","n":"Enzymatica AB: Bulletin from annual general meeting 2018 in Enzymatica AB (publ)","u":"/media/press-releases/2018/enzymatica-ab-bulletin-from-annual-general-meeting-2018-in-enzymatica-ab-publ/"},{"d":"2018-04-26","n":"Enzymatica AB: Continued growth during the first quarter","u":"/media/press-releases/2018/enzymatica-ab-continued-growth-during-the-first-quarter/"},{"d":"2018-04-11","n":"Enzymatica AB: New results from Enzymatica's in vitro study: ColdZyme also deactivates corona virus","u":"/media/press-releases/2018/enzymatica-ab-new-results-from-enzymaticas-in-vitro-study-coldzyme-also-deactivates-corona-virus/"},{"d":"2018-04-11","n":"Stefansson et al, ColdZyme forms a protective barrier in the throat that deactivates five major common cold viruses, Congress of the Swedish Association of Otolaryngology, 2018_Abstract","u":"/media/press-releases/2018/stefansson-et-al-coldzyme-forms-a-protective-barrier-in-the-throat-that-deactivates-five-major-common-cold-viruses-congress-of-the-swedish-association-of-otolaryngology-2018_abstract/"},{"d":"2018-04-11","n":"Stefansson et al, ColdZyme forms a protective barrier in the throat that deactivates five major common cold viruses, Congress of the Swedish Association of Otolaryngology, 2018_Poster","u":"/media/press-releases/2018/stefansson-et-al-coldzyme-forms-a-protective-barrier-in-the-throat-that-deactivates-five-major-common-cold-viruses-congress-of-the-swedish-association-of-otolaryngology-2018_poster/"},{"d":"2018-04-09","n":"Enzymatica AB: New ColdZyme study in elite athletes confirms preventive effect and reduced duration of illness","u":"/media/press-releases/2018/enzymatica-ab-new-coldzyme-study-in-elite-athletes-confirms-preventive-effect-and-reduced-duration-of-illness/"},{"d":"2018-03-28","n":"Enzymatica AB: Enzymatica - publication of the annual report 2017","u":"/media/press-releases/2018/enzymatica-ab-enzymatica---publication-of-the-annual-report-2017/"},{"d":"2018-03-21","n":"Enzymatica AB: Notice of annual general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2018/enzymatica-ab-notice-of-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2018-02-14","n":"Enzymatica AB: Strong growth and international breakthrough in 2017","u":"/media/press-releases/2018/enzymatica-ab-strong-growth-and-international-breakthrough-in-2017/"},{"d":"2017-12-27","n":"New customer survey – ColdZyme prevents colds and reduces severity and duration among cold sufferers","u":"/media/press-releases/2017/new-customer-survey--coldzyme-prevents-colds-and-reduces-severity-and-duration-among-cold-sufferers/"},{"d":"2017-11-29","n":"Enzymatica AB: Enzymatica's Nomination Committee for the Annual General Meeting 2018 appointed","u":"/media/press-releases/2017/enzymatica-ab-enzymaticas-nomination-committee-for-the-annual-general-meeting-2018-appointed/"},{"d":"2017-11-14","n":"Enzymatica AB: Enzymatica announces a study showing the ability of ColdZyme to deactivate major common cold viruses","u":"/media/press-releases/2017/enzymatica-ab-enzymatica-announces-a-study-showing-the-ability-of-coldzyme-to-deactivate-major-common-cold-viruses/"},{"d":"2017-11-09","n":"Enzymatica AB: ColdZyme study - Most recommended cold product at pharmacies","u":"/media/press-releases/2017/enzymatica-ab-coldzyme-study---most-recommended-cold-product-at-pharmacies/"},{"d":"2017-11-01","n":"Enzymatica AB: Interim report for Enzymatica AB (publ) January-September 2017","u":"/media/press-releases/2017/enzymatica-ab-interim-report-for-enzymatica-ab-publ-january-september-2017/"},{"d":"2017-10-25","n":"Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2017/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2017-10-18","n":"Enzymatica AB: Complete article from COLDPREV I study published - strengthens documentation for ColdZyme","u":"/media/press-releases/2017/enzymatica-ab-complete-article-from-coldprev-i-study-published---strengthens-documentation-for-coldzyme/"},{"d":"2017-10-17","n":"Enzymatica AB: ColdZyme cold spray reduces sickness absence among preschool staff","u":"/media/press-releases/2017/enzymatica-ab-coldzyme-cold-spray-reduces-sickness-absence-among-preschool-staff/"},{"d":"2017-09-25","n":"Enzymatica AB: Notice of extraordinary general meeting regarding among other things personnel option program in Enzymatica AB (publ)","u":"/media/press-releases/2017/enzymatica-ab-notice-of-extraordinary-general-meeting-regarding-among-other-things-personnel-option-program-in-enzymatica-ab-publ/"},{"d":"2017-09-06","n":"Enzymatica recruits Chief Financial Officer","u":"/media/press-releases/2017/enzymatica-recruits-chief-financial-officer/"},{"d":"2017-07-20","n":"Enzymatica AB: Continued sales growth and breakthrough order from STADA","u":"/media/press-releases/2017/enzymatica-ab-continued-sales-growth-and-breakthrough-order-from-stada/"},{"d":"2017-07-18","n":"Enzymatica recruits Chief Commercial Officer","u":"/media/press-releases/2017/enzymatica-recruits-chief-commercial-officer/"},{"d":"2017-07-14","n":"Enzymatica recruits Chief Operating Officer","u":"/media/press-releases/2017/enzymatica-recruits-chief-operating-officer/"},{"d":"2017-06-21","n":"A study of elite athletes shows that ColdZyme provides protection as evidenced by fewer sick days and lost training days, as well as improved quality of life","u":"/media/press-releases/2017/a-study-of-elite-athletes-shows-that-coldzyme-provides-protection-as-evidenced-by-fewer-sick-days-and-lost-training-days-as-well-as-improved-quality-of-life/"},{"d":"2017-06-14","n":"Enzymatica receives record order from STADA Arzneimittel AG","u":"/media/press-releases/2017/enzymatica-receives-record-order-from-stada-arzneimittel-ag/"},{"d":"2017-05-23","n":"Bengt Jöndell continues as acting CFO","u":"/media/press-releases/2017/bengt-jondell-continues-as-acting-cfo/"},{"d":"2017-04-20","n":"Enzymatica AB: Bulletin from annual general meeting 2017 in Enzymatica AB (publ)","u":"/media/press-releases/2017/enzymatica-ab-bulletin-from-annual-general-meeting-2017-in-enzymatica-ab-publ/"},{"d":"2017-04-20","n":"Enzymatica AB: Breakthrough in Germany and continued increase in sales","u":"/media/press-releases/2017/enzymatica-ab-breakthrough-in-germany-and-continued-increase-in-sales/"},{"d":"2017-04-06","n":"Enzymatica AB: Enzymatica - publication of the annual report 2016","u":"/media/press-releases/2017/enzymatica-ab-enzymatica---publication-of-the-annual-report-2016/"},{"d":"2017-04-05","n":"Enzymatica AB: Completing the Nomination Committee's in Enzymatica AB proposal for AGM 2017 regarding election of auditor","u":"/media/press-releases/2017/enzymatica-ab-completing-the-nomination-committees-in-enzymatica-ab-proposal-for-agm-2017-regarding-election-of-auditor/"},{"d":"2017-03-21","n":"Enzymatica AB: Notice of annual general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2017/enzymatica-ab-notice-of-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2017-02-16","n":"Enzymatica AB: Geographic expansion and continued growth in 2016","u":"/media/press-releases/2017/enzymatica-ab-geographic-expansion-and-continued-growth-in-2016/"},{"d":"2017-02-13","n":"Enzymatica AB: Enzymatica enters into partnership agreement with STADA Arzneimittel AG","u":"/media/press-releases/2017/enzymatica-ab-enzymatica-enters-into-partnership-agreement-with-stada-arzneimittel-ag/"},{"d":"2016-12-22","n":"ColdZyme demonstrates reduced sick leave during cold season","u":"/media/press-releases/2016/coldzyme-demonstrates-reduced-sick-leave-during-cold-season/"},{"d":"2016-12-21","n":"Enzymatica AB: Top-line results of new clinical trial","u":"/media/press-releases/2016/enzymatica-ab-top-line-results-of-new-clinical-trial/"},{"d":"2016-12-19","n":"Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2016/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2016-12-01","n":"Enzymatica AB: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (publ)","u":"/media/press-releases/2016/enzymatica-ab-notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ/"},{"d":"2016-12-01","n":"Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors","u":"/media/press-releases/2016/enzymatica-ab-extraordinary-shareholders-meeting-on-changes-to-the-board-of-directors/"},{"d":"2016-11-09","n":"Medical case report on promising treatment with ColdZyme® of patients with primary immunodeficiency","u":"/media/press-releases/2016/medical-case-report-on-promising-treatment-with-coldzyme-of-patients-with-primary-immunodeficiency/"},{"d":"2016-11-03","n":"Enzymatica AB: ColdZyme® sales continue to perform well","u":"/media/press-releases/2016/enzymatica-ab-coldzyme-sales-continue-to-perform-well/"},{"d":"2016-11-02","n":"Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health","u":"/media/press-releases/2016/enzymatica-ab-enzymatica-signs-distribution-agreement-with-endeavour-consumer-health/"},{"d":"2016-08-30","n":"Enzymatica AB: The board of directors in Enzymatica has resolved on a directed share issue of SEK 40.3 million","u":"/media/press-releases/2016/enzymatica-ab-the-board-of-directors-in-enzymatica-has-resolved-on-a-directed-share-issue-of-sek-403-million/"},{"d":"2016-07-18","n":"Enzymatica AB: Excellent volume growth for ColdZyme®","u":"/media/press-releases/2016/enzymatica-ab-excellent-volume-growth-for-coldzyme/"},{"d":"2016-05-25","n":"Bulletin from the Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2016/bulletin-from-the-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2016-05-11","n":"Enzymatica's new rights issue completed - will be provided with SEK 60 million","u":"/media/press-releases/2016/enzymaticas-new-rights-issue-completed---will-be-provided-with-sek-60-million/"},{"d":"2016-05-03","n":"Enzymatica insiders plan to subscribe for SEK 16 million in new issue","u":"/media/press-releases/2016/enzymatica-insiders-plan-to-subscribe-for-sek-16-million-in-new-issue/"},{"d":"2016-04-27","n":"Customer studies: ColdZyme users fight colds early and actively","u":"/media/press-releases/2016/customer-studies-coldzyme-users-fight-colds-early-and-actively/"},{"d":"2016-04-26","n":"Notice of annual general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2016/notice-of-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2016-04-20","n":"Enzymatica publishes prospectus","u":"/media/press-releases/2016/enzymatica-publishes-prospectus/"},{"d":"2016-04-20","n":"Information about Enzymatica’s new rights issue","u":"/media/press-releases/2016/information-about-enzymaticas-new-rights-issue/"},{"d":"2016-04-20","n":"Enzymatica - publication of the annual report 2015","u":"/media/press-releases/2016/enzymatica---publication-of-the-annual-report-2015/"},{"d":"2016-04-18","n":"Interim Report for Enzymatica AB (publ) January-March 2016","u":"/media/press-releases/2016/interim-report-for-enzymatica-ab-publ-january-march-2016/"},{"d":"2016-04-14","n":"Bulletin from the extraordinary shareholders' meeting in Enzymatica","u":"/media/press-releases/2016/bulletin-from-the-extraordinary-shareholders-meeting-in-enzymatica/"},{"d":"2016-04-01","n":"Enzymatica completes acquisition of Zymetech and includes new board members and representative to the nomination committee","u":"/media/press-releases/2016/enzymatica-completes-acquisition-of-zymetech-and-includes-new-board-members-and-representative-to-the-nomination-committee/"},{"d":"2016-03-24","n":"Acting CFO of Enzymatica appointed","u":"/media/press-releases/2016/acting-cfo-of-enzymatica-appointed/"},{"d":"2016-03-17","n":"Enzymatica AB: Updated time plan for the acquisition of Zymetech and the rights issue","u":"/media/press-releases/2016/enzymatica-ab-updated-time-plan-for-the-acquisition-of-zymetech-and-the-rights-issue/"},{"d":"2016-03-15","n":"Enzymatica announces new dates for its financial information","u":"/media/press-releases/2016/enzymatica-announces-new-dates-for-its-financial-information/"},{"d":"2016-03-15","n":"NOTICE OF EXTRAORDINARY SHAREHOLDERS MEETING IN ENZYMATICA AB (PUBL)","u":"/media/press-releases/2016/notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ/"},{"d":"2016-03-15","n":"The board of directors in Enzymatica has resolved on a rights issue of SEK 60 million","u":"/media/press-releases/2016/the-board-of-directors-in-enzymatica-has-resolved-on-a-rights-issue-of-sek-60-million/"},{"d":"2016-02-16","n":"Enzymatica AB: Strong growth in 2015 and acquisition for international expansion","u":"/media/press-releases/2016/enzymatica-ab-strong-growth-in-2015-and-acquisition-for-international-expansion/"},{"d":"2016-02-15","n":"Bulletin from the extraordinary shareholders' meeting in Enzymatica","u":"/media/press-releases/2016/bulletin-from-the-extraordinary-shareholders-meeting-in-enzymatica-2016-02-15/"},{"d":"2016-02-03","n":"Enzymatica moves forward its year-end report for 2015","u":"/media/press-releases/2016/enzymatica-moves-forward-its-year-end-report-for-2015/"},{"d":"2016-01-28","n":"NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (PUBL)","u":"/media/press-releases/2016/notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ-2016-01-28/"},{"d":"2016-01-28","n":"Enzymatica signs acquisition agreement and prepares for international expansion with new share issue","u":"/media/press-releases/2016/enzymatica-signs-acquisition-agreement-and-prepares-for-international-expansion-with-new-share-issue/"},{"d":"2016-01-28","n":"Frequently asked questions and answers about Enzymatica's acquisition of Zymetech","u":"/media/press-releases/2016/frequently-asked-questions-and-answers-about-enzymaticas-acquisition-of-zymetech/"},{"d":"2016-01-27","n":"Questions and Answers – regarding the ASA decision, for marketing- and web material of ColdZyme in the UK","u":"/media/press-releases/2016/questions-and-answers--regarding-the-asa-decision-for-marketing--and-web-material-of-coldzyme-in-the-uk/"},{"d":"2015-11-12","n":"Enzymatica signs distribution agreement with Esteve in Spain","u":"/media/press-releases/2015/enzymatica-signs-distribution-agreement-with-esteve-in-spain/"},{"d":"2015-11-10","n":"Enzymatica signs distribution agreement with Tamro for the Finnish market","u":"/media/press-releases/2015/enzymatica-signs-distribution-agreement-with-tamro-for-the-finnish-market/"},{"d":"2015-10-16","n":"Enzymatica strengthens its presence in the UK through collaboration with the Lloyds pharmacy chain","u":"/media/press-releases/2015/enzymatica-strengthens-its-presence-in-the-uk-through-collaboration-with-the-lloyds-pharmacy-chain/"},{"d":"2014-11-17","n":"Fredrik Lindberg appointed CEO of Enzymatica","u":"/media/press-releases/2014/fredrik-lindberg-appointed-ceo-of-enzymatica/"},{"d":"2014-10-13","n":"Launch in Denmark expands ColdZyme® to all of Scandinavia","u":"/media/press-releases/2014/launch-in-denmark-expands-coldzyme-to-all-of-scandinavia/"},{"d":"2014-09-11","n":"New Chairman of the Board at Enzymatica","u":"/media/press-releases/2014/new-chairman-of-the-board-at-enzymatica/"},{"d":"2014-09-09","n":"Enzymatica appoints acting CEO","u":"/media/press-releases/2014/enzymatica-appoints-acting-ceo/"},{"d":"2014-07-24","n":"Enzymaticas veterinary products launched at the AVMA Annual Convention in Denver, USA","u":"/media/press-releases/2014/enzymaticas-veterinary-products-launched-at-the-avma-annual-convention-in-denver-usa/"},{"d":"2014-07-09","n":"Enzymatica: ColdZyme to be introduced in the UK","u":"/media/press-releases/2014/enzymatica-coldzyme-to-be-introduced-in-the-uk/"},{"d":"2014-06-11","n":"Enzymatica: ColdZyme to be introduced at pharmacies in Norway","u":"/media/press-releases/2014/enzymatica-coldzyme-to-be-introduced-at-pharmacies-in-norway/"},{"d":"2014-05-23","n":"Enzymatica presents COLDPREV study at scientific congress in Copenhagen","u":"/media/press-releases/2014/enzymatica-presents-coldprev-study-at-scientific-congress-in-copenhagen/"},{"d":"2014-05-19","n":"Bulletin from the Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2014/bulletin-from-the-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2014-05-15","n":"Clarification: Shareholder proposals for the 2014 Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2014/clarification-shareholder-proposals-for-the-2014-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2014-05-05","n":"Enzymatica’s 2013 Annual Report now available","u":"/media/press-releases/2014/enzymaticas-2013-annual-report-now-available/"},{"d":"2014-04-25","n":"New date for Enzymaticas Interim Report January-March: May 19, 2014","u":"/media/press-releases/2014/new-date-for-enzymaticas-interim-report-january-march-may-19-2014/"},{"d":"2014-04-09","n":"Enzymaticas rights issue oversubscribed","u":"/media/press-releases/2014/enzymaticas-rights-issue-oversubscribed/"},{"d":"2014-02-12","n":"Enzymatica signs agreement for the sale of ColdZyme® at Swedish airports","u":"/media/press-releases/2014/enzymatica-signs-agreement-for-the-sale-of-coldzyme-at-swedish-airports/"},{"d":"2014-02-10","n":"Enzymatica announces launch plan for a proprietary mouthwash for gingivitis","u":"/media/press-releases/2014/enzymatica-announces-launch-plan-for-a-proprietary-mouthwash-for-gingivitis/"},{"d":"2014-02-03","n":"Enzymatica strengthens its organisation","u":"/media/press-releases/2014/enzymatica-strengthens-its-organisation/"},{"d":"2013-12-16","n":"Enzymatica increases turnover of 2013 – far beyond its financial goal","u":"/media/press-releases/2013/enzymatica-increases-turnover-of-2013--far-beyond-its-financial-goal/"},{"d":"2013-12-12","n":"Enzymatica expands its own Scandinavian operation and moves internationally with partners","u":"/media/press-releases/2013/enzymatica-expands-its-own-scandinavian-operation-and-moves-internationally-with-partners/"},{"d":"2013-12-02","n":"Enzymatica gets full market coverage through wholesale agreement with Tamro","u":"/media/press-releases/2013/enzymatica-gets-full-market-coverage-through-wholesale-agreement-with-tamro/"},{"d":"2013-11-06","n":"Enzymatica to offer new product line and sets up a subsidiary in the USA","u":"/media/press-releases/2013/enzymatica-to-offer-new-product-line-and-sets-up-a-subsidiary-in-the-usa/"},{"d":"2013-10-02","n":"Enzymatica: ColdZyme® Mouth Spray on pharmacy chain Medstop’s shelves","u":"/media/press-releases/2013/enzymatica-coldzyme-mouth-spray-on-pharmacy-chain-medstops-shelves/"},{"d":"2013-09-10","n":"Enzymatica conducts a directed issue totalling SEK 19 million","u":"/media/press-releases/2013/enzymatica-conducts-a-directed-issue-totalling-sek-19-million/"},{"d":"2013-09-09","n":"The COLDPREV study: ColdZyme Mouth Spray reduces both the viral load and the number of sick days with common cold in infected individuals, compared with placebo","u":"/media/press-releases/2013/the-coldprev-study-coldzyme-mouth-spray-reduces-both-the-viral-load-and-the-number-of-sick-days-with-common-cold-in-infected-individuals-compared-with-placebo/"},{"d":"2013-08-14","n":"Broad launch for ColdZyme® Mouth Spray, soon on Apoteket AB’s shelves","u":"/media/press-releases/2013/broad-launch-for-coldzyme-mouth-spray-soon-on-apoteket-abs-shelves/"},{"d":"2013-05-31","n":"Enzymatica signs agreement with Actavis for ColdZyme in the Nordic region","u":"/media/press-releases/2013/enzymatica-signs-agreement-with-actavis-for-coldzyme-in-the-nordic-region/"},{"d":"2013-05-06","n":"Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2013/annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2013-04-10","n":"Enzymatica starts the process for listing on the Stockholm Stock Exchange","u":"/media/press-releases/2013/enzymatica-starts-the-process-for-listing-on-the-stockholm-stock-exchange/"},{"d":"2013-04-05","n":"Anders Jungbeck proposed as new member of the Board of Enzymatica","u":"/media/press-releases/2013/anders-jungbeck-proposed-as-new-member-of-the-board-of-enzymatica/"},{"d":"2013-03-21","n":"Christian W. Jansson is proposed as the new Chairman of the Board of Enzymatica","u":"/media/press-releases/2013/christian-w-jansson-is-proposed-as-the-new-chairman-of-the-board-of-enzymatica/"},{"d":"2013-03-21","n":"New date for Enzymatica’s Annual General Meeting","u":"/media/press-releases/2013/new-date-for-enzymaticas-annual-general-meeting/"},{"d":"2013-01-17","n":"Enzymatica to commence clinical market-monitoring study for the prevention and shortening of upper airway infection","u":"/media/press-releases/2013/enzymatica-to-commence-clinical-market-monitoring-study-for-the-prevention-and-shortening-of-upper-airway-infection/"},{"d":"2013-01-15","n":"Enzymatica: ColdZyme® Mouth Spray – for treating the common cold – to be introduced by the Swedish Apotek Hjärtat pharmacy chain","u":"/media/press-releases/2013/enzymatica-coldzyme-mouth-spray--for-treating-the-common-cold--to-be-introduced-by-the-swedish-apotek-hjartat-pharmacy-chain/"},{"d":"2012-12-21","n":"Enzymatica published in the international journal Infectious Diseases & Therapy – promising method for the prevention of colds using ColdZyme Mouth Spray","u":"/media/press-releases/2012/enzymatica-published-in-the-international-journal-infectious-diseases--therapy--promising-method-for-the-prevention-of-colds-using-coldzyme-mouth-spray/"},{"d":"2012-12-19","n":"Enzymatica signs agreement with the Kronans Droghandel pharmacy chain","u":"/media/press-releases/2012/enzymatica-signs-agreement-with-the-kronans-droghandel-pharmacy-chain/"},{"d":"2012-10-11","n":"Enzymatica announces Fredrik Håkansson as its new CFO","u":"/media/press-releases/2012/enzymatica-announces-fredrik-hakansson-as-its-new-cfo/"},{"d":"2012-10-02","n":"Mats Clarsund new EVP Research & Development at Enzymatica","u":"/media/press-releases/2012/mats-clarsund-new-evp-research--development-at-enzymatica/"},{"d":"2012-09-19","n":"Enzymatica inaugurates Scientific Advisory Board","u":"/media/press-releases/2012/enzymatica-inaugurates-scientific-advisory-board/"},{"d":"2012-08-13","n":"Enzymatica’s ColdZyme® Mouth Spray against common cold is registered with the Swedish Medical Product Agency","u":"/media/press-releases/2012/enzymaticas-coldzyme-mouth-spray-against-common-cold-is-registered-with-the-swedish-medical-product-agency/"}]